CTNM
insider transactionsContineum Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-48.4K
0 buy · 48.4K sell
Net value · 365d
-$697.7K
$0 in · $697.7K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
19
0 buy · 48.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Scientific Officer · 10b5-1
$54.9K
4.2K sh · $13.16
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$4.2K
300 sh · $13.84
Own -0%
-
Sell·S
Chief Scientific Officer · 10b5-1
$50.5K
3.9K sh · $13.06
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$56.0K
4.2K sh · $13.43
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$62.6K
4.2K sh · $15.01
Own -3%
-
Exercise·M
CMO & Head of Development · 10b5-1
$0
3.6K sh
Own +1%
-
Sell·S
CMO & Head of Development · 10b5-1
$54.2K
3.6K sh · $15.02
Own -100%
-
Exercise·M
CMO & Head of Development · 10b5-1
$16.2K
3.6K sh · $4.50
Own New
-
Exercise·M
CEO and President · 10b5-1
$0
2.7K sh
Own +2%
-
Sell·S
CEO and President · 10b5-1
$43.2K
2.7K sh · $16.02
Own -15%
-
Exercise·M
CEO and President · 10b5-1
$3.4K
2.7K sh · $1.26
Own +18%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
3.8K sh
Own +6%
-
Sell·S
Chief Scientific Officer · 10b5-1
$61.2K
3.8K sh · $16.01
Own -2%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$3.9K
3.8K sh · $1.01
Own +2%
-
Exercise·M
CEO and President · 10b5-1
$0
4.4K sh
Own +4%
-
Sell·S
CEO and President · 10b5-1
$70.5K
4.4K sh · $16.02
Own -23%
-
Exercise·M
CEO and President · 10b5-1
$5.5K
4.4K sh · $1.26
Own +29%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
4.3K sh
Own +6%
-
Sell·S
Chief Scientific Officer · 10b5-1
$68.9K
4.3K sh · $16.03
Own -3%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$4.3K
4.3K sh · $1.01
Own +3%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
100 sh
Own +0%
-
Sell·S
Chief Scientific Officer · 10b5-1
$1.6K
100 sh · $16.00
Own -0%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$101
100 sh · $1.01
Own +0%
-
Exercise·M
CEO and President · 10b5-1
$0
400 sh
Own +0%
-
Sell·S
CEO and President · 10b5-1
$6.4K
400 sh · $16.00
Own -3%
-
Exercise·M
CEO and President · 10b5-1
$504
400 sh · $1.26
Own +3%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
400 sh
Own +1%
-
Sell·S
Chief Scientific Officer · 10b5-1
$6.4K
400 sh · $16.00
Own -0%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$404
400 sh · $1.01
Own +0%
-
Sell·S
Chief Scientific Officer · 10b5-1
$17.8K
1.2K sh · $15.25
Own -1%
-
Sell·S
Chief Scientific Officer · 10b5-1
$44.5K
3.0K sh · $14.82
Own -2%
-
Grant·A
General Counsel and Corp Sec
$0
206.4K sh
Own New
-
Grant·A
Peter T Slover KEY
Chief Financial Officer
$0
192.0K sh
Own New
-
Grant·A
CEO and President
$0
445.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
6.5K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
160.0K sh
Own New
-
Grant·A
CMO & Head of Development · 10b5-1
$0
160.0K sh
Own New
-
Exercise·M
CMO & Head of Development · 10b5-1
$0
3.6K sh
Own +1%
-
Sell·S
CMO & Head of Development · 10b5-1
$11.7K
811 sh · $14.48
Own -100%
-
Sell·S
CMO & Head of Development · 10b5-1
$39.4K
2.8K sh · $14.09
Own -78%
-
Exercise·M
CMO & Head of Development · 10b5-1
$16.2K
3.6K sh · $4.50
Own New
-
Sell·S
Chief Scientific Officer · 10b5-1
$5.6K
500 sh · $11.13
Own -0%
-
Sell·S
Chief Scientific Officer · 10b5-1
$38.0K
3.7K sh · $10.35
Own -2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 4.2K | $54.9K |
| May 1, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 300 | $4.2K |
| May 1, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 3.9K | $50.5K |
| Apr 6, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 4.2K | $56.0K |
| Mar 2, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 4.2K | $62.6K |
| Mar 2, 2026 | Tim Watkins 10b5-1 | Exercise M | 3.6K | $0 |
| Mar 2, 2026 | Tim Watkins 10b5-1 | Sell S | 3.6K | $54.2K |
| Mar 2, 2026 | Tim Watkins 10b5-1 | Exercise M | 3.6K | $16.2K |
| Feb 25, 2026 | Carmine N. Stengone KEY 10b5-1 | Exercise M | 2.7K | $0 |
| Feb 25, 2026 | Carmine N. Stengone KEY 10b5-1 | Sell S | 2.7K | $43.2K |
| Feb 25, 2026 | Carmine N. Stengone KEY 10b5-1 | Exercise M | 2.7K | $3.4K |
| Feb 25, 2026 | Daniel S. Lorrain 10b5-1 | Exercise M | 3.8K | $0 |
| Feb 25, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 3.8K | $61.2K |
| Feb 25, 2026 | Daniel S. Lorrain 10b5-1 | Exercise M | 3.8K | $3.9K |
| Feb 24, 2026 | Carmine N. Stengone KEY 10b5-1 | Exercise M | 4.4K | $0 |
| Feb 24, 2026 | Carmine N. Stengone KEY 10b5-1 | Sell S | 4.4K | $70.5K |
| Feb 24, 2026 | Carmine N. Stengone KEY 10b5-1 | Exercise M | 4.4K | $5.5K |
| Feb 24, 2026 | Daniel S. Lorrain 10b5-1 | Exercise M | 4.3K | $0 |
| Feb 24, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 4.3K | $68.9K |
| Feb 24, 2026 | Daniel S. Lorrain 10b5-1 | Exercise M | 4.3K | $4.3K |
| Feb 19, 2026 | Daniel S. Lorrain 10b5-1 | Exercise M | 100 | $0 |
| Feb 19, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 100 | $1.6K |
| Feb 19, 2026 | Daniel S. Lorrain 10b5-1 | Exercise M | 100 | $101 |
| Feb 11, 2026 | Carmine N. Stengone KEY 10b5-1 | Exercise M | 400 | $0 |
| Feb 11, 2026 | Carmine N. Stengone KEY 10b5-1 | Sell S | 400 | $6.4K |
| Feb 11, 2026 | Carmine N. Stengone KEY 10b5-1 | Exercise M | 400 | $504 |
| Feb 11, 2026 | Daniel S. Lorrain 10b5-1 | Exercise M | 400 | $0 |
| Feb 11, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 400 | $6.4K |
| Feb 11, 2026 | Daniel S. Lorrain 10b5-1 | Exercise M | 400 | $404 |
| Feb 3, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 1.2K | $17.8K |
| Feb 3, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 3.0K | $44.5K |
| Jan 30, 2026 | John Stephen Healy | Grant A | 206.4K | $0 |
| Jan 30, 2026 | Peter T Slover KEY | Grant A | 192.0K | $0 |
| Jan 30, 2026 | Carmine N. Stengone KEY | Grant A | 445.0K | $0 |
| Jan 30, 2026 | Daniel S. Lorrain | Grant A | 6.5K | $0 |
| Jan 30, 2026 | Daniel S. Lorrain | Grant A | 160.0K | $0 |
| Jan 30, 2026 | Tim Watkins 10b5-1 | Grant A | 160.0K | $0 |
| Jan 28, 2026 | Tim Watkins 10b5-1 | Exercise M | 3.6K | $0 |
| Jan 28, 2026 | Tim Watkins 10b5-1 | Sell S | 811 | $11.7K |
| Jan 28, 2026 | Tim Watkins 10b5-1 | Sell S | 2.8K | $39.4K |
| Jan 28, 2026 | Tim Watkins 10b5-1 | Exercise M | 3.6K | $16.2K |
| Jan 5, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 500 | $5.6K |
| Jan 5, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 3.7K | $38.0K |
About CTNM insider trading
This page tracks insider transactions for Contineum Therapeutics, Inc. (CTNM) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.